Michael Staehler
Overview
Explore the profile of Michael Staehler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
175
Citations
7092
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Staehler M, Basso U, Eymard J, Barthelemy P, Bigot P, Laramas M, et al.
Clin Genitourin Cancer
. 2024 Dec;
23(1):102285.
PMID: 39740313
Background: There is a lack of published data on real-world cabozantinib use in patients with advanced renal cell carcinoma after prior vascular endothelial growth factor (VEGF)-targeted therapy. Methods: CASSIOPE was...
2.
Grunwald V, McKay R, Buchler T, Eto M, Park S, Takagi T, et al.
Int J Cancer
. 2024 Dec;
156(7):1326-1335.
PMID: 39739622
Lenvatinib plus pembrolizumab significantly improved efficacy versus sunitinib in treatment of advanced renal cell carcinoma (aRCC) in the phase 3 CLEAR study. We report results of an exploratory post hoc...
3.
Pyrgidis N, Volz Y, Ebner B, Westhofen T, Staehler M, Chaloupka M, et al.
Eur Urol Focus
. 2024 Aug;
PMID: 39209568
Background And Objective: Major urological guidelines do not currently recommend robot-assisted surgery compared with laparoscopic or open surgery due to the lack of high-quality evidence. We aimed to provide real-world...
4.
Leonard S, Helstrom E, Correa A, Sindhani M, Uzzo N, Jia A, et al.
JCO Oncol Pract
. 2024 Jul;
20(12):1755-1763.
PMID: 39008789
Purpose: This study leverages CDC National Health Interview Survey data to examine Financial Distress (FD) among genitourinary (GU) cancer survivors, specifically prostate cancer (PC), kidney cancer (KC), and bladder cancer...
5.
Tan V, Correa R, Warner A, Ali M, Muacevic A, Ponsky L, et al.
Eur Urol Oncol
. 2024 Jul;
7(6):1527-1534.
PMID: 38987159
Background And Objective: Renal function preservation is particularly important following nonoperative treatment of localized renal cell carcinoma (RCC) since patients are often older with medical comorbidities. Our objective was to...
6.
Hofmann T, Kohlhase N, Eftimova D, Eder M, Staehler M, Ruge M, et al.
Phys Med
. 2024 May;
122:103372.
PMID: 38759469
Purpose: Although emerging clinical evidence supports robotic radiosurgery as a highly effective treatment option for renal cell carcinoma (RCC) less than 4 cm in diameter, delivery uncertainties and associated target...
7.
Marvaso G, Jereczek-Fossa B, Zaffaroni M, Vincini M, Corrao G, Andratschke N, et al.
Lancet Oncol
. 2024 May;
25(5):e193-e204.
PMID: 38697165
The purpose of this European Society for Radiotherapy and Oncology (ESTRO) project, endorsed by the European Association of Urology, is to explore expert opinion on the management of patients with...
8.
Pyrgidis N, Schulz G, Stief C, Blajan I, Ivanova T, Graser A, et al.
Cancers (Basel)
. 2024 Jan;
16(1).
PMID: 38201523
Background: We aimed to evaluate the current trends in renal cancer surgery, as well as to compare the perioperative outcomes of partial versus radical nephrectomy. Methods: We used the GeRmAn...
9.
Bui V, Unterrainer L, Brendel M, Kunte S, Holzgreve A, Allmendinger F, et al.
Biomedicines
. 2023 Nov;
11(11).
PMID: 38002095
In renal cell carcinoma (RCC), accurate imaging methods are required for treatment planning and response assessment to therapy. In addition, there is an urgent need for new therapeutic options, especially...
10.
Staehler M, Rodler S, Brinkmann I, Stief C, Graser A, Gotz M, et al.
Clin Genitourin Cancer
. 2023 Nov;
22(2):189-192.
PMID: 37985332
Introduction: Renal biopsy is recommended if the outcome might alter therapeutic decisions for patients who present with renal masses of unclear etiology. However, little is known about long-term risks related...